Will Cyclopharm’s (ASX:CYC) UPHS Agreement Accelerate US Expansion?

Sonal Goyal

23 March 2026 04:54 PM AEDT

Will Cyclopharm’s (ASX:CYC) UPHS Agreement Accelerate US Expansion?

Image Source: shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Cyclopharm signs a multi-site agreement with the University of Pennsylvania Health System (UPHS) across 11 clinical locations in Pennsylvania and New Jersey.
Share price increased 4.166% to $0.750, with a market capitalization of $86.97 million.
Two immediate Technegas® installations at high-volume centers, with potential for recurring consumables and service revenue.
Initial contract term: 3 years, with expansion potential to additional sites within UPHS-affiliated networks.
Agreement positions Cyclopharm for system-wide adoption across US Integrated Delivery Networks (IDNs).

Cyclopharm Limited (ASX:CYC) has achieved a strategic milestone by securing a multi-site agreement with UPHS, one of the top 20 hospitals in the US.

The agreement covers installation of Technegas® systems—a proprietary functional lung imaging radiopharmaceutical—at 11 sites. This represents a lighthouse adoption in the Mid-Atlantic corridor, providing immediate scale, recurring revenue, and a platform for further regional expansion.

Share Performance and Market Reaction

Following the announcement, Cyclopharm shares rose $0.030 (4.166%) to $0.750. Trading volume was 23,341 shares, with a bid/offer range of $0.750–$0.795.

The market responded positively due to the high-quality US institutional partnership, potential for recurring consumables revenue, and the strategic significance of establishing reference sites in major academic medical centers.

Multi-Site Agreement Details

Key elements of the UPHS agreement include:

Immediate Installations: Two sites operational immediately—Hospital of the University of Pennsylvania and Perelman Center for Advanced Medicine.
Network Coverage: Nine additional sites to follow, with potential for expansion beyond the initial 11 locations.
Revenue Model: Installation fees, annual support, and recurring per-patient consumables.
Contract Duration: Initial term of three years, providing visibility for medium-term revenue.
Strategic Benefits: Provides a reference cluster within a nationally recognized academic system, supporting broader US expansion.

Strategic and Clinical Importance

Cyclopharm’s Technegas® technology is traditionally used for pulmonary embolism (PE) imaging but is increasingly applied to:

COPD and asthma assessment
Interstitial lung disease monitoring
Oncology-related pulmonary evaluations
Pre-surgical planning (e.g., lobectomies, lung volume reduction)

The UPHS agreement enhances Cyclopharm’s commercial leverage, accelerates clinical adoption, and positions the company as a leader in functional lung imaging within US integrated health networks.

US Commercial Momentum

The UPHS deal highlights Cyclopharm’s strategy to:

Establish reference sites at high-profile academic medical centers.
Build regional density for scalable system adoption.
Expand across IDNs, leveraging multi-site agreements to increase recurring consumables and service revenue.

Cyclopharm’s Managing Director and CEO, James McBrayer, emphasized that multi-site agreements are central to driving scalable revenue growth and enhancing operating leverage as utilisation increases.

Revenue Outlook and Operational Benefits

Immediate Revenue Generation: Two high-volume sites provide near-term consumables revenue.
Recurring Revenue: Technegas® generates ongoing consumables and service income per patient procedure.
Scalable Platform: Initial network adoption can expand to additional UPHS sites and other IDNs in the US.
Market Leadership: Secures a prominent presence in Philadelphia and the wider Mid-Atlantic healthcare corridor.

Risks and Considerations

Potential risks include:

Adoption Rate: Revenue depends on clinical uptake across all sites.
Regulatory Compliance: US nuclear medicine regulations require ongoing adherence to FDA and NRC standards.
Competition: Other imaging modalities or new technologies could affect market share.

Cyclopharm mitigates these risks through partnerships with high-profile academic institutions and a focus on expanding Beyond PE applications.

Conclusion

Cyclopharm’s multi-site UPHS agreement represents a significant milestone in US expansion:

Provides immediate revenue from high-volume, prestigious academic sites.
Establishes a regional reference cluster supporting broader IDN adoption.
Enhances recurring revenue potential through consumables and support services.
Positions Cyclopharm as a leader in functional lung imaging, extending beyond traditional pulmonary embolism applications.

With this deal, Cyclopharm strengthens its US commercial footprint and reinforces its growth strategy in a high-value, recurring revenue market.

Frequently Asked Questions (FAQs)

What is Cyclopharm’s current share price and market cap?

Shares closed at $0.750, with a market capitalization of $86.97 million.

What is Technegas®?

Technegas® is a radioactive carbon-based gas used in functional lung imaging for diagnosing PE, COPD, asthma, and lung-related oncology procedures.

How many sites are included in the UPHS agreement?

11 clinical locations across Pennsylvania and New Jersey, with potential for expansion.

What revenue streams does Cyclopharm gain from this agreement?

Revenue comes from installation fees, annual service/support fees, and recurring per-patient consumables.

How does this deal support US expansion?

Creates a lighthouse adoption cluster, enabling regional density and system-wide penetration across large integrated healthcare networks.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.